https://doi.org/10.4081/btvb.2022.36
Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study
Submitted: 5 May 2022
Accepted: 1 June 2022
Published: 14 July 2022
Accepted: 1 June 2022
Abstract Views: 928
PDF: 202
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Circulating albumin and fibrinogen levels, commonly considered as inflammatory markers, have been shown to be associated with venous thromboembolism (VTE) risk. Circulating albumin-to-fibrinogen ratio (AFR) has been proposed as a novel inflammatory biomarker, but its association with VTE risk has not been investigated. We aimed to assess the prospective association of AFR with VTE risk. Circulating albumin and fibrinogen levels were measured at baseline in 2,284 men aged 42-61 years. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. During a median follow-up of 27.0 years, 156 VTE cases were recorded. In analysis adjusted for established risk factors, the HR (95% CI) for VTE comparing extreme tertiles of AFR was 1.53 (1.02-2.32), which remained similar on further adjustment for prevalent cancer, 1.52 (1.01-2.30). The associations of circulating albumin or fibrinogen with VTE risk were modest. Circulating AFR may be a stronger risk indicator for VTE compared with albumin or fibrinogen alone.
Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-2.
DOI: https://doi.org/10.1161/ATVBAHA.108.162545
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015;12:464-74.
DOI: https://doi.org/10.1038/nrcardio.2015.83
Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007;44:62-9.
DOI: https://doi.org/10.1053/j.seminhematol.2007.02.004
Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-9.
DOI: https://doi.org/10.1055/s-0037-1615887
Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005;94:362-5.
DOI: https://doi.org/10.1160/TH05-04-0266
Kunutsor SK, Sameul S, Blom AW, et al. Serum C-reactive protein increases the risk of venous thromboembolism: A prospective study and meta-analysis of published prospective evidence Eur J Epidemiol 2017 32:657-67.
DOI: https://doi.org/10.1007/s10654-017-0277-4
Kunutsor SK, Seidu S, Katechia DT, Laukkanen JA. Inverse association between serum albumin and future risk of venous thromboembolism: interrelationship with high sensitivity C-reactive protein. Ann Med 2018:1-9.
DOI: https://doi.org/10.1080/07853890.2018.1441537
Klovaite J, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis. Am J Respir Crit Care Med 2013;187:286-93.
DOI: https://doi.org/10.1164/rccm.201207-1232OC
Chi G, Gibson CM, Liu Y, et al. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol 2019;94:21-8.
DOI: https://doi.org/10.1002/ajh.25296
Lin C, Chen Y, Chen B, et al. D-Dimer Combined with Fibrinogen Predicts the Risk of Venous Thrombosis in Fracture Patients. Emerg Med Int 2020;2020:1930405.
DOI: https://doi.org/10.1155/2020/1930405
Wang J, Xi H, Zhang K, et al. Circulating C-Reactive Protein to Prealbumin Ratio and Prealbumin to Fibrinogen Ratio are Two Promising Inflammatory Markers Associated with Disease Activity in Rheumatoid Arthritis. Clin Lab 2020;66.
DOI: https://doi.org/10.7754/Clin.Lab.2019.190833
Simera I, Moher D, Hoey J, et al. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
DOI: https://doi.org/10.1111/j.1365-2362.2009.02234.x
Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988;20:46-50.
Kunutsor SK, Khan H, Laukkanen JA. Serum albumin concentration and incident type 2 diabetes risk: new findings from a population-based cohort study. Diabetologia 2015;58:961-7.
DOI: https://doi.org/10.1007/s00125-015-3520-0
Liu Z, Mi J. Serum Albumin and Circulating Metabolites and Risk of Venous Thromboembolism: A Two-Sample Mendelian Randomization Study. Front Nutr 2021;8:712600.
DOI: https://doi.org/10.3389/fnut.2021.712600
Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010;104:100-4.
DOI: https://doi.org/10.1160/TH09-12-0856
Shaper AG, Wannamethee SG, Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004;57:195-202.
DOI: https://doi.org/10.1016/j.jclinepi.2003.07.001
Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995;16A:11-4.
DOI: https://doi.org/10.1093/eurheartj/16.suppl_A.11
Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) 1995;89:205-14.
DOI: https://doi.org/10.1042/cs0890205
How to Cite
Kunutsor, S. K., Kurl, S., Voutilainen, A. ., & Laukkanen, J. (2022). Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study. Bleeding, Thrombosis and Vascular Biology, 1(2). https://doi.org/10.4081/btvb.2022.36
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Kartik Akkihal, Thomas Varkey, James Kelbert, The use of creatine and the development of deep vein thrombosis. A scoping review , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- Luca Puccetti, Vincenzo Sammartano, Federico Caroni, Margherita Malchiodi, Paola Calzoni, Eleonora Franceschini, Lucrezia Galasso, Monica Bocchia, Safety of COVID-19 mRNA vaccination in patients with history of acquired hemophilia A: a case series , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Luca Barcella, Chiara Ambaglio, Paolo Gritti, Francesca Schieppati, Varusca Brusegan, Eleonora Sanga, Marina Marchetti, Luca Lorini, Anna Falanga, Long-term persistence of high anti-PF4 antibodies titer in a challenging case of AZD1222 vaccine-induced thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Daniela Poli, Emilia Antonucci, Gualtiero Palareti, Roberto Facchinetti, Pietro Falco, Giuseppina Serricchio, Teresa Lerede, Lucilla Masciocco, Paolo Gresele, Sophie Testa, Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Stefano Lancellotti, Monica Sacco, Maira Tardugno, Antonietta Ferretti, Raimondo De Cristofaro, The Von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Cristina Legnani, Michela Cini, Sophie Testa, Alberto Tosetto, Claudia Dellanoce, Stefania Bellesso, Giuseppe Carli, Ilaria Nichele, Laura Lissandrini, Serena Zorzi, Emilia Antonucci, Gualtiero Palareti, Evaluation of Coaguchek®Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Marialaura Bonaccio, Licia Iacoviello, Maria Benedetta Donati, It’s definitely time to consider diet in its ultra-processing form as a major risk factor for thrombotic vascular disorders , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Paolo Prandoni, New perspectives for prevention of the post-thrombotic syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Silvia Cardi, Filippo Catalani, Luca Valerio, Stefano Barco, From rare to aware: confronting Lemierre syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- Marco P. Donadini, Walter Ageno, Milvexian and other drugs targeting Factor XI: a new era of anticoagulation? , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
You may also start an advanced similarity search for this article.
